Shilpa Medicare Limited has informed the Exchange about Investor Presentation
Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739
Date: 26 May 2025
To Corporate Relationship Department BSE Limited, 1st Floor, Rotunda Building, P.J. Towers, Dalal Street, Mumbai – 400 001.
To National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No.C/1, G Block Bandra Kurla Complex, Bandra (E) Mumbai – 400 051.
Scrip Code: BSE - 530549/ Stock Symbol: NSE – SHILPAMED
Dear Sir/Madam,
Sub: Investor Presentation of the Company for the quarter & year ended 31 March 2025 Ref: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
With reference to the captioned subject, the Investor Presentation for the quarter and year ended 31 March 2025, on Company Overview, Business highlights, financial performance and other updates is enclosed herewith for your consideration.
We request you to take the same on record.
A copy of this intimation is also being made available at:
https://vbshilpa.com/investor-presentation.php
Thanking you
For Shilpa Medicare Limited,
Ritu Tiwary Company Secretary & Compliance Officer
Shilpa Medicare Ltd 4QFY25 Earnings Presentation
Date: 26th May 2025
Safe Harbour
Certain statements in this document may be forward - looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Shilpa Medicare Limited (SML) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.
2
Shilpa Medicare at a glance
Established in 1987, we have 35+ years track record
Existing Business Segments: API , Formulation, CDMO, Biologics
Emerging Businesses: NDDS, ADC and Recombinant Human Albumin
10+ Regulatory approved manufacturing + R&D facilities (incl Analytical Lab)
400+ R&D Personnel
500+ Regulatory Filings across the world
Worldwide presence in 50+ countries
FY25 Financials
Revenue INR 1,310 crores (+13% YoY) EBITDA INR 340 crores (+35% YoY)
3
Company snapshot
API
Formulations
Biosimilars
CDMO
Recombinant Albumin
▪ The business comprises of
production of APIs (oncology and non- oncology), Peptides, Polymers and intermediates.
▪ With a focus on introducing generic molecules that face entry barriers, Specialization in complex API processes for both oncology and non- oncology molecules
▪ Differentiated portfolio of Onco and Non- Onco products including 505 (b)(2) with focus on ease of administration for patients. ▪ We Develop, manufacture & License of a wide range of products, including oral solids, liquid injections, dry powder injectable products, orally disintegrating films (ODFs), transdermal patches and lyophilised injectables
▪ Offering Biosimilar portfolio
across niche therapies such as Oncology, immunotherapy, and Ophthalmology
▪ End-to-end biologics CDMO services for drug substances (mammalian and microbial) and drug products
▪ “Clone-to-vial" capabilities make Shilpa Biologicals the preferred one-stop outsourcing partner. ▪ Strong capabilities to
▪ Integrated, one stop CMC solutions for development and manufacturing of preclinical, clinical and commercial
▪ Capabilities include
developing & Manufacturing DS and DP for Small Molecules and complex chemistries. ▪ Servicing to various global
biotech companies including 10+ big pharma clients
▪ Ready capacities available for
manufacture ADCs and GLP-1 products
large molecule CDMO biologics
• Developed & patented a novel rHA (recombinant Human Albumin) process which is
• Environment friendly • Highly scalable • High-Quality consistency • Cost competitive
FY25 Revenue – INR 736 crs
FY25 Revenue – INR 474 crs
FY25 Revenue – INR 75 crs
FY25 Revenue – INR 158 crs*
Pre revenue stage
*CDMO revenue is a part of respective divisions
4
Key operating verticals
FY25 Revenue contribution
Legal Entities
Areas of Operation
API
Formulations
Biologics
6%
57%
37%
▪ Shilpa Pharma Lifesciences
▪ Oncology ▪ Non-Oncology ▪ HpAPI ▪ Peptides ▪ Polymers ▪ ADCs ▪ CDMO
▪ Shilpa Medicare ▪ Shilpa Therapeutics ▪ FTF Pharma
▪ Tablets/Capsules ▪ Injectables ▪ Oral Dissolving Films ▪ Transdermal patches ▪ CDMO
▪ Shilpa Biologicals ▪ Shilpa Biocare
▪ NBE ▪ Microbials Products ▪ Mammalian Products ▪ GLP-1 ▪ CDMO
API Includes others
5
Management Commentary
FY25 performance reflects our pursuit of differentiated business model enabling us to grow with improved profitability.
In FY25, Shilpa Medicare has emerged stronger, turning years of strategic investments and relentless perseverance into remarkable achievements in differentiated initiatives like launch of two NDAs in US market, filing of transdermal patch product in EU, SEC clearance of Nor-UDCA in India and OLC filing by our partner with US FDA. Our unwavering commitment to innovation and R&D has borne fruit, with significant breakthrough in out licensing our flagship product – Recombinant Human Albumin, for commercialization across EU region in strategic partnership with Orion Corporation.
Besides this, we also saw a very successful year on the regulatory front, as we received EIR for our API unit 1, along with EU GMP certifications for our FDF Unit 6 (having ODF & TDP manufacturing capabilities) and for our Biologics unit. I believe this will help in enabling us to further scale up our Biologics CDMO platform and give us the opportunity to monetize our Biosimilar pipeline for large regulated markets.
With asset utilization improvement across key verticals, we remain confident of delivering improved profitability in FY26. As we advance, we remain committed to leveraging our R&D strengths, regulatory compliance, and operational agility to create long-term value.
— Mr. Vishnukant Bhutada Managing Director
6
4QFY25 Performance
7
4Q FY25 – Financial Performance
4Q FY25 (Consolidated)
Particulars (INR cr)
4QFY25
4QFY24
Total Revenue
Gross Profit
GP Margin
EBITDA
EBITDA Margin
Adjusted PAT*
PAT Margin
338
234
69%
84
25%
33
10%
294
197
67%
73
25%
20
7%
YoY
15%
19%
200 bps
15%
-
65%
300 bps
3QFY25
QoQ
320
229
72%
82
26%
32
10%
6%
2%
-300 bps
2%
-100 bps
3%
-
Revenue Break-up (INR in cr.)
Biologicals, 10.0
Others, 8.0
5%
4Q FY25
Formulation, 133.0
39%
API, 188.0
56%
Result commentary ▪ ▪ Gross margins for the quarter came in at 69%, improving 200 bps YoY
Revenue grew by 15% on YoY basis, driven by healthy performance in our fast-growing FDF vertical
▪ Gross margins improved despite lower Licensing income and lower CDMO revenue on YoY basis
▪ ▪ ▪
EBITDA grew by 15% YoY at INR 84crs; EBITDA Margins at 25% Exceptional item consists of settlement with Celltrion INC amounting to ~INR 29crs *Adjusted to Exceptional Item (net of tax), PAT stood at INR 33crs which showed an increase of ~65% YoY
All numbers are rounded off to nearest one
8
FY25 – Financial Performance
FY25 (Consolidated)
Particulars (INR cr)
Total Revenue
Gross Profit
GP Margin
EBITDA
EBITDA Margin
Adjusted PAT*
PAT Margin
FY25
1,310
899
69%
340
26%
97
7%
FY24
1,160
752
65%
253
22%
28
2%
YoY (%)
13%
20%
400bps
35%
400bps
246%
500bps
Revenue Break-up (INR in cr.)
Biologicals, 75.0
Others, 25.0
2%
7%
FY25
Formulation, 474.0
37%
API, 736.0
54%
Revenue grew by 13% on a YoY basis, driven by healthy performance across our key verticals viz. FDF & Biologics
Result commentary ▪ ▪ Gross margins continue to improve at 69%, driven by better product mix ▪ ▪ ▪
EBITDA for FY25 stood at INR 340crs higher by 35% YoY; EBITDA Margins at ~26% Exceptional item consist of settlement with Celltrion INC amounting to ~INR 29crs *Adjusted to Exceptional Item (net of tax), PAT stood at INR 97crs which has grown over 2x YoY
All numbers are rounded off to nearest one
9
Consolidated Performance
Revenues
EBITDA and Margins
(INR in Cr.)
294
320
338
4QFY24
3QFY25
4QFY25
1,160
FY24
1,310
FY25
25%
25%
26%
73
82
84
26%
340
253
22%
4QFY24
3QFY25
4QFY25
FY24
FY25
PBT and Margins
13%
13%
7%
22
42
43
4%
48
11%
151
PAT and Margins
7%
20
10%
10%
32
33
4QFY24
3QFY25
4QFY25*
FY24
FY25*
Q4FY24
Q3FY25
Q4FY25*
*4Q & FY25 PBT & PAT are adjusted to Exceptional item consisting of settlement with Celltrion INC amounting to ~INR 29crs
97
7%
FY25*
28
2%
FY24
10
Financial Summary
ROCE
Gross Block (INR crs)
8%
6%
9%
1%
2%
1,256
1,538
1,587
1,670
1,991
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
Net Debt to EBITDA (x)
Net Capex (INR crs)
6.7
5.8
3.4
3
1.6
349
331
225
172
216
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
11
API Business
12
API – Muted growth; order book remains healthy
184
183
188
2
18
92
72
6
25
71
81
11 5
94
78
772
15 54
348
355
736
23
67
318
328
Oncology
Non-Oncology
CDMO
Others
Oncology Non-Oncology
CDMO Others
4QFY24
3QFY25
4QFY25
FY24
FY25
▪
▪
▪
(INR in Cr.)
4QFY25 Revenue growth was driven by portfolio rationalization and improved offtake of key products, coupled with contribution from newly increased capacities for key products
Completed capacity expansion for key products viz. UDCA, Tranexamic Acid, Azacitidine, Palbociclib and Nilotinib. To drive incremental growth from FY26 onwards
Rationalizing portfolio towards higher margin product and markets. Expanding product portfolio with launches in multiple complex APIs and Specialty portfolio
▪ Added new clients in various
geographies
13
API – Ongoing Developments
API Molecules
CDMO
▪ Commercialized Increased capacities for key
products viz. UDCA, Tranexamic Acid and Onco molecules
▪ Initiated validation for 4 new products
▪ Received CEP from EDQM for Teriflunomide
▪ Added 2 new customers, taking the total count to 20+
▪ Successfully Completed Phase II supply for a multi-step complex chemistry project, offering One-Stop-Solution for drug substance and drug product development for US client.
▪ In our ongoing NDA program, where we serve as our partner’s
CDMO, secured FDA’s clearance to conduct Ph2 trials for additional indication and subsequently partner has received fast track designation
▪ New dedicated block for OLC expected to be commercialized in
FY26
Polymer and Peptide ▪ Commercial manufacturing started of large polymer
project worth ~USD 4mn received from a US MNC for non pharma applications. Sole supplier from India, with order value expected to increase going forward.
▪ Developed a process for synthesizing polymer with varying molecular weights, widely used in biomedical applications, including drug delivery and tissue engineering
▪ GLP 1 - Liraglutide dossier filing and Semaglutide plant
scaleup planned in 1QFY26
▪ Initiated commercial batch scale up for CEP approved
▪ Increase in number of RFQs received from various global biotech
peptide APIs
API – DMF Filings
60
45
35
23
22
17
14
10
12
USFDA
EU/EMEA
GCC & ROW
MFDS
Canada
Australia
China
PMDA Japan
Russia
New product introduction and increase in geographical coverage replicated with 246 DMF filings with major regulatory authorities Successfully concluded US FDA inspection and received EIR for Unit 1 Unit 2 audit with US FDA was completed with Zero observations, EIR awaited
8
NZ
14
Formulations Business
15
New product launches drive FDF revenue growth
97
118
133
346
34
5 10
19
29
46
6 17
35
14
24
7
44
49
9
153
20 33
86
54
474
181
25
100
120
48
US
Europe
RoW Domestic
Licensing/ Services
US
Europe
RoW Domestic
Licensing/Services
4QFY24
3QFY25
4QFY25
FY24
FY25
▪
▪
▪
(INR in Cr.) For the quarter, the division reported robust revenue growth of 38% on YoY basis
Launched our 2nd NDA viz. Bortezomib RTU Subcutaneous in US, scale up expected in FY26.
Received EU approval for Tadalafil ODF in EU region. Received approval for Varenicline tablets for US market
▪ Nilotinib drove strong growth in
EU region
▪ All 3 approved NDAs have limited competition. More NDAs will be filed in coming quarters
▪
Submitted remediation work with the US FDA for re-inspection of Jadcherla Unit
16
FDF – Update on key assets
NorUDCA SMLNUD07
▪ CDSCO approved Ph3 clinical trials and recommended for market authorization approval, Launch planned in 1HFY26 ▪ The product will be first NCE launch for NAFLD disease treatment for company
SMLTDP08
SMLTOP09
SMLODF010
SMLINJ011
ODF & TDS
▪ Expected to launch in European market in FY26
▪ Transdermal Patch for treatment of Parkinson’s disease ▪ US Study initiated in
4QFY25
▪ Europe submission completed in 2Q FY25 by our partner and expecting a limited competition launch in FY26
▪ Topical lotion for treatment of Androgenic Alopecia ▪ Phase II completed, and data submitted to Indian regulatory body; Phase III study to start post approval
▪ EU Scientific advice
filed
▪ Injection for
▪ Two new transdermal
patch product development completed.
▪ Initiated pilot study for One product in EU market and planned studies for another product in 1HFY26 ▪ The product is complex and uniquely positioned with no generic competition
▪ Tadalafil ODF approved in EU market, launch expected in FY26
prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, radiotherapy and other associated medication. Market Size is ~$931 mn (Global)*
▪ Initiated Ph3 clinical
studies in India ▪ Responses received
from scientific advises filed in EU and US Pre IND; basis of response further studies are planned
*Source: IQVIA – MAT-June 24
17
Filings – Formulations
Formulations – Regulatory Filings
Pending
Approved
30
16
14
US ANDA and NDA
81
73
8
EU
10
6
4
Canada
552
285
267
ROW
Robust regulatory filings to strengthen the base for growth in the formulation segment Our ODF & TDP manufacturing Unit 6 received GMP approval from EMA (European Medicines Agency)
18
CDMO Business
19
CDMO – Strong capabilities in various technologies
Shilpa Medicare
Peer 1
Peer 2
Peer 3
Global Peer 1
Global Peer 2
Global Peer 3
Very strong capability
Strong capability
Developing capability
Negligible capability
Indian CDMOs
Global CDMOs
Specialized technologies
Small molecule
Peptide
Monoclonal Antibodies and Recombinant technology
Antibody – Drug conjugates
Fermentation
Offerings
Development
Manufacturing
▪ Early phase to late phase from AI/ML led discovery (target to hit, hit to lead and lead to NCE) to custom synthesis, scale up and clinical materials (for advanced intermediates,
RSMs
▪ “Clone-to-vial" capabilities makes us a preferred one-stop outsourcing partner, securing strong market position ▪ Leveraging expertise to offer interconnected tech platform for various fast growing opportunities in the areas of fermentation, Antibody-Drug Conjugates (ADCs), and GLP-1 ▪ Leveraging exquisite strengths in complex chemistry across pharma and specialty chemicals. Integrated CMC approach for delivering drug substance and drug product to pharma
customers
20
Robust business model encompassing various stages
Value chain stages
Development & Clinical supplies
Late stage development & Commercial Manufacturing
Phases
Pre-Clinical Development
Clinical development & Supplies
Registration
Commercial Manufacturing
▪ Drug metabolism, pharmacokinetics (DMPK)
▪ Phase 3 clinical trials
Key steps
▪ Toxicology studies (Safety studies)
▪ Manufacturing clinical supplies
▪ Phase 1 and 2 clinical trails
▪ Drug filing with regulatory authorities
▪ Drug substance manufacturing (RSM, intermediates, APIs) and formulation
Number of projects
20+
3
21
Comprehensive CDMO Development
Unicycive Therapeutics Inc’s Oxylanthanum Carbonate (OLC) is a Potential best-in-class product being developed under FDA’s 505(b)(2) regulatory pathway for the treatment of hyperphosphatemia
Long term manufacturing and supply agreement with SML.
SML is receiving significant milestone income spanning over various stages viz. filing, approval and launch of the product
NDA accepted by the US FDA with potential approval FY26
Building back-end to develop & manufacture both API & Formulation
Product Profile1 ▪ Potential best-in-class product for the treatment of Hyperphosphatemia ▪ Advantages: (1) Potency: Shares high phosphate binding capacity of
lanthanum; (2) Pill Burden: Smaller and fewer pills; (3) Palatability: swallowed whole with water and not chewed
▪ A comprehensive CDMO contract for both API and formulation
development – a One-stop-Solution
▪ Unicycive announced successful trial results and FDA acceptance of its New Drug Application for OLC, with PDUFA June 28, 2025, potentially easing treatment for hyperphosphatemia in CKD dialysis patients.
1. Source: Unicycive Presentation
22
Biologics & NBE
23
Biologics – Growth envisioned on 4 pillars
Biologics
Novel Biologics
Integrated CDMO @Dharwad
Other Key updates
▪ Adalimumab: India market to grow 2x in FY26 based on approval of additional indications (Crohn’s disease and Ulcerative colitis in adults). Filing in progress in 15 RoW markets, with approvals expected in FY26
▪ Aflibercept: Ophthalmic biologic with a global market size of ~USD 9 bn1 initiated into Ph3 with expected launch in FY26. Out-licensed to two partners in India and Russia, with multiple discussions in MENA region
▪ Nivolumab (USD 10 bn) 1,
Pembrolizumab (USD 30 bn) 1 small scale development completed and PCT initiated. Clinical initiation targeted in FY26
▪ Daratumumab (USD 6 bn) 1 and
Dupilumab (USD 16 bn) 1 cell line development initiated, PCT in FY26 ▪ Trastuzumab (USD 4 bn) 1 process
development completed
1. Global Market share, Source: IQVIA – MAT-June 24
▪ Novel MAB (oncology): Term sheet signed with mABTree. Expecting Cell line in 1HFY26 and targeting for investigator led trials in late FY26
▪ 2 CDMO projects in
pharmaceutical segment are ongoing
▪ Signed 1 large microbial-based
project with long term manufacturing contract ▪ Signed 1 mammalian-based
project
▪ 1 New project in food sector
signed in Dec 2024 ▪ Extensive BD efforts are
planned for expanding business in this segment
▪ Increase in number of RFQs received from various global biotech
▪ Biologics site at Dharwad
received EU GMP approval ▪ Received GMP certification approval from Oman MoH
▪ In process of building
differentiated capacities in ADCs
▪ Building bioconjugation suite for Drug Substance ▪ Leveraging our HpAPI for
Linker and Payload
▪ Leveraging our
formulations site for fill finish work
24
Why Recombinant Human Albumin ?
Predictable & assured supply – Product in yeast (Pichia pastoris) by fermentation
All raw materials used in the production are free from animal sources
High quality/Purity Meets Global standards
Freedom from potential contamination sources – inherently free from HIV, HBV, HCV, Prion contamination
Best in class productivity – makes the product competitive in comparison to plasma Albumin
25
Shilpa’s Recombinant Human Albumin
Key highlights
Shilpa’s novel rHA (Recombinant Human Albumin)
Regulatory filing status
Addressing the global unmet need
IP Positioning
▪ Entered into a strategic partnership with Orion Corporation for commercialization in Europe region ▪ Under this agreement, Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa’s
Recombinant Human Albumin in Europe
▪ Shilpa is entitled to receive from Orion certain development and regulatory milestone payments ▪ Shilpa has been investing in the development of this novel product for about 8 years and has also set-up a large scale
fermentation facility for manufacturing
▪ India – Initiating Ph3 trials in FY26
▪ EU – EU scientific advice submitted
▪ US – Scientific advice to be filed, with feedback expected by 1HFY26
▪ Non-Therapeutic - Samples shared with few clients in US
▪ Shilpa has developed recombinant Human Albumin (rHA)
▪ Targets to fulfil growing demand of human serum albumin.
▪ All the raw materials used in manufacturing are animal origin free (AOF)
▪ Shilpa’s Recombinant Human Albumin production technology is covered by patents in developed markets viz. US &
Europe
26
Outlook FY26 and beyond
FDF 6 key products (NDA- Pemetrexed, NDA – Bortezomib, Nilotinib, Axitinib, Rotigotine and NorUDCA) launches/Scale up to drive revenue materially
CDMO Commercial launch of OLC in US to kick start significant revenue Other late-stage assets progressing well
API Multiple complex API launches, growth in Specialty portfolio, coupled with capacity expansion for existing key products to drive API growth
Biologics Strong Biosimilar pipeline with various large assets completing clinical trails, coupled with niche CDMO Biologic offerings to drive Biosimilar revenue growth in significant manner from late FY26
Recombinant Albumin Ph3 trials for India to start in FY26. Strategic tie up with Orion Corporation. Non – therapeutic usage is being explored
Licensing income Various assets where licensing income was received are moving towards commercial long term supply agreements
Impending Operating Leverage Substantial portion of current gross block remains under utilized having spread across high margin divisions viz. Biosimilar, CDMO and NDDS
Margin Improvement Improved utilization is likely to drive meaningful improvement in revenue and EBITDA margins
27
Manufacturing Capabilities – API & Biocare
API Unit 1 - Raichur
API Unit 2 - Raichur
Biocare - Kadechur
Capabilities
Onco, Non-Onco APIs and peptide, having competence for gram-to-kilo scale synthesis
Isolation, purification, separation techniques.
• • Asymmetric synthesis. • Chiral technology. • CDMO
• Fully automated integrated facility with DCS
control system
• Filtration system for protein separation
Capacities
• 11 mfg blocks (4 onco and 7 non-onco) • Total reactor capacity of 650 KL
• 10 mfg blocks (5 onco and 5 non onco) • Total reactor capacity of 510 KL
Regulatory Accreditation
• USFDA • EUGMP • TGA • PMFDA • KFDA
• WHO-GMP • TPD
• WHO-GMP • TPD
• USFDA • EUGMP • TGA • PMFDA • KFDA
• 200KL+ Fermentation capacity • Capacities ranging from 5 KL to 50 KL for
product vessels and 5 KL to 15 KL for buffer vessels
• Audit ready
28
Manufacturing Capabilities – Formulations & Biologics
Formulations - Jadcherla
Formulations - Bangalore
Biologics - Dharwad
Capabilities
OSD tablets and capsules; Injectables – dry powder and liquid lyophilization
Fully automated facility for Transdermal patches and Oral Thin Films
Capacities
Injectable - ~3mn Liquid Vials Lyophilized - ~2mn Vials OSD – 25mn Tablets Capsules – 4mn Hard Capsules
Regulatory Accreditation
EU GMP, ANVISA, COFEPRIS, TGA, WHO-GMP, SHAPRA, Health Canada
ODF - ~50mn Units TDF - ~30mn Units
End-to-end services, from development to commercial manufacturing of microbial & mammalian-based drug substance and drug products. Having expertise in complex technologies viz. ADC, peptides and conjugated proteins
Upstream – 4000LX2 Microbial Suite – SS 1000LX2 PFS – 80 units/min
WHO-GMP, UK-MHRA, EU GMP
• EU GMP, DSIR Approved facility
29
Financials
30
Profit & Loss Consolidated
Particulars (INR cr)
4Q FY25
4Q FY24
YoY
3Q FY25
QoQ
Revenues
Gross Profit
Gross Margin %
Employee Cost
Other Expenses
EBITDA
338
234
69%
71
79
84
294
197
67%
66
58
73
EBITDA Margin %
25%
25%
Finance Cost
Depreciation
Adj PBT*
Adj PAT*
15
29
43
33
24
27
22
20
15%
19%
7%
36%
15%
-38%
7%
95%
65%
320
230
72%
74
74
82
26%
12
29
42
32
6%
2%
-4%
7%
2%
25%
-
2%
3%
FY25
1,310
FY24
1,160
899
69%
293
266
340
26%
76
113
150
97
752
65%
282
218
253
22%
92
108
48
28
*4Q & FY25 PBT & PAT are adjusted to Exceptional item consisting of settlement with Celltrion INC amounting to ~INR 29crs
All numbers are rounded off to nearest one
YoY
13%
20%
4%
22%
35%
-17%
5%
212%
246%
31
Balance Sheet Consolidated
Particulars (INR crs)
Fixed Assets
▪
▪
Tangible Assets
Intangible Assets
Capital WIP
▪
▪
Tangible Assets
Intangible Assets
Other Non-current Assets
Net Working Capital
▪
▪
▪
Current Assets
Cash and cash equivalents
Current Liabilities
Total Assets ( Net)
▪
▪
Equity
Borrowings (Current & Non-current)
▪ Other Non-Current Liabilities
Total Liabilities
All numbers are rounded off to nearest one
31-Mar-25
1,418
1,212
205
822
463
359
73
666
957
29
-320
2,978
2,364
586
28
2,978
31-Dec-24
1,425
1,214
211
754
423
332
109
647
899
19
-270
2,935
2,352
549
34
2,935
31-Mar-24
1,385
1,193
192
719
403
316
103
558
845
32
-318
2,765
1,800
936
29
2,765
32
Earnings call Details
Shilpa Medicare 4QFY25 Results Conference Call to be held May 26, 2025, Monday at 17:00
Details of Earnings Conference Call
Universal Access
+91 22 6280 1130 +91 22 7115 8031
The number listed above is universally accessible from all networks and all countries
International Toll-Free Numbers
USA UK Singapore Hong Kong
18667462133 08081011573 8001012045 800964448
DiamondPass
Link
Click here to join with DiamondPass
(No Wait Time)
33
Shilpa Medicare Limited
Monish Shah
+91 2249748754
monish.shah@vbshilpa.com
THANK YOU!
Ernst & Young IR
Runjhun Jain/Sneha Salian
+91 98207 20993 / +91 98194 30437
runjhun.jain1@in.ey.com / sneha2.salian@in.ey.com
34